ScreenerHero

BNTC Benitec Biopharma Inc.

NAS · US · Healthcare · Biotechnology · benitec.com
8.990USD-0.11%Mkt Cap: 313.60M $P/E: —

Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines in the United States. Its Silence and Replace, a DNA-directedRNA interference platform, that combines …

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap313.60M USD
Enterprise Value134.73M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-45.55M USD
Revenue/Share—
Last Price8.990 USD
Fiscal Year EndJun 2026
MR QuarterJun 2026
Employees24
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-0.96
PEG—
EV/EBITDA-2.63
EV/Revenue—
P/S—
P/B1.75
EPS (TTM)-0.98
EPS (Forward)-9.42
52W Range
8.5206% of range16.76
52W High16.76 USD
52W Low8.520 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-25.73%
ROA-24.94%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-16.52M USD
CapEx (TTM)105.00K USD
FCF Margin—
FCF Yield-0.88%
Net Debt-179.21M USD
Net Debt/EBITDA3.50
Balance Sheet
Debt/Equity0.00
Current Ratio34.00
Quick Ratio33.68
Book Value/Sh5.14 USD
Cash/Share5.16 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateNov 18, 2019
Splits
Last Split1:17
Split DateJul 26, 2023
Analyst Consensus
Rating1.1 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)24.33 USD
Upside (mean)+170.7%
Target Range17.00 USD – 32.00 USD
17.00+170.7% to mean32.00
# Analysts6
Ownership
Shares Out.34.88M
Float18.45M
Insiders2.51%
Institutions96.07%
Short Interest
Short Ratio16.2d
Short % Float10.96%
Short % Out.6.27%
Shares Short2.19M
Short (prev mo.)2.11M
Technical
SMA 5011.89 (-24.4%)
SMA 20011.89 (-24.4%)
Beta0.25
S&P 52W Chg16.45%
Avg Vol (30d)162.24K
Avg Vol (10d)226.90K
Technical Indicators
RSI (14)29.1
MACD-0.8621
MACD Signal-0.7489
MACD Hist.-0.1132
BB Upper13.04 USD
BB Middle10.51 USD
BB Lower7.981 USD
BB Width48.10%
ATR (14)0.7873 USD
Vol Ratio (20d)1.03x